cathepsin S

01/01/2014 - "Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis."
05/24/2006 - "Inhibition of cathepsin S with compound I may be useful in the treatment of human autoimmune diseases like rheumatoid arthritis and multiple sclerosis."
07/01/2006 - "An oral cathepsin S inhibitor that blocks MHCII antigen presentation could result in a T-cell-selective immunosuppressant agent with improved safety over the current standard of care for the treatment of rheumatoid arthritis, psoriasis, multiple sclerosis and other autoimmune-based inflammatory diseases. "
05/25/2005 - "The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel anti-resorptive drugs in osteoporosis whereas cathepsin S appears to be an attractive drug target candidate for various inflammatory diseases including rheumatoid arthritis. "
10/01/2015 - "Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies."

10/01/2008 - "The brain-penetrating cathepsin S inhibitors demonstrate potential clinical utility for the treatment of multiple sclerosis and neuropathic pain."
05/24/2006 - "Inhibition of cathepsin S with compound I may be useful in the treatment of human autoimmune diseases like rheumatoid arthritis and multiple sclerosis."
07/01/2006 - "An oral cathepsin S inhibitor that blocks MHCII antigen presentation could result in a T-cell-selective immunosuppressant agent with improved safety over the current standard of care for the treatment of rheumatoid arthritis, psoriasis, multiple sclerosis and other autoimmune-based inflammatory diseases. "

05/01/2011 - "The purpose of the study was to examine the potential of inhibition of cathepsin S as a treatment for autoimmune diseases. "
08/01/2002 - "Studies described here examine the functional significance of cathepsin S inhibition on autoantigen presentation and organ-specific autoimmune diseases in a murine model for Sjögren syndrome. "
06/01/2013 - "Cathepsin S is a potential target of autoimmune disease. "
11/01/2010 - "Cathepsin S is a critical protease for the regulation of MHC class II immune responses, and thus is a potential target for developing immunosuppressive drugs in the pathogenesis of degenerative and autoimmune diseases. "
07/01/2004 - "As a result, cathepsin S has been implicated as a potential target in the treatment of various disorders ranging from autoimmune diseases to atherosclerosis. "

09/25/2008 - "Recently, our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. "
09/25/2008 - "Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain."
01/01/2008 - "Differential expression of Cathepsin S and X in the spinal cord of a rat neuropathic pain model."
06/19/2007 - "Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain."
09/25/2008 - "Herein, we describe the efficacy of selective cathepsin S inhibitors as antihyperalgesics in a model of neuropathic pain in rats after oral administration."

02/01/2012 - "We have previously shown that the specific inhibition of Cathepsin S using a monoclonal antibody (Fsn0503) blocks colorectal carcinoma tumour growth and angiogenesis in vivo. "
11/08/2011 - "The aim of this pilot retrospective study was to investigate the immunohistochemical expression of Cathepsin S (CatS) in three cohorts of colorectal cancer (CRC) patients (n=560). "
01/01/2011 - "Our analysis of colorectal cancer patient biopsies shows that cathepsin S associates with the cell membrane indicating a potential for ADCC targeting. "
10/01/2009 - "A selected cathepsin S antibody, Fsn0503, significantly blocked invasion of a range of tumor cell lines, most significantly HCT116 colorectal carcinoma cells, through inhibition of extracellular cathepsin S-mediated proteolysis. "
10/01/2009 - "Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis."